Profile of infliximab in the treatment of pediatric Crohn’s disease

In recent years, a novel biologic therapy with monoclonal antibodies against tumor necrosis factor-alpha has revolutionized the treatment of Crohn’s disease. Infliximab, the first biologic agent, has been demonstrated to considerably improve both clinical and endoscopic outcomes. In view of the grow...

Descripción completa

Detalles Bibliográficos
Autores principales: Kierkus, Jaroslaw, Szymanska, Edyta, Oracz, Grzegorz, Wiernicka, Anna, Dadalski, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683274/
https://www.ncbi.nlm.nih.gov/pubmed/29388577
http://dx.doi.org/10.2147/PHMT.S64943
Descripción
Sumario:In recent years, a novel biologic therapy with monoclonal antibodies against tumor necrosis factor-alpha has revolutionized the treatment of Crohn’s disease. Infliximab, the first biologic agent, has been demonstrated to considerably improve both clinical and endoscopic outcomes. In view of the growing popularity of infliximab in the management of Crohn’s disease, we review the profile of the agent in the treatment of this disease in a pediatric setting.

Ejemplares similares